In a latest research printed within the JAMA Community Open, a gaggle of researchers evaluated the influence of train, glucagon-like peptide-1 receptor agonist (GLP-1 RA) liraglutide, and their mixture on bone well being on the hip, backbone, and forearm following diet-induced weight reduction in adults with weight problems.
Research: Bone Well being After Train Alone, GLP-1 Receptor Agonist Therapy, or Mixture Therapy. Picture Credit score: siamionau pavel / Shutterstock
Background
Weight reduction reduces obesity-related comorbidities however typically results in decreased bone mineral density (BMD) and elevated bone turnover, elevating fracture danger and mortality. This bone loss is a priority throughout the lifespan, notably in older adults, and is noticed after gastric bypass and calorie restriction. Figuring out remedies that induce weight reduction whereas minimizing bone loss is essential. GLP-1RAs promote weight reduction by suppressing urge for food. Train is really helpful for wholesome weight reduction because it preserves lean mass. Additional analysis is required to determine the long-term results of GLP-1 RAs and train on bone well being following vital weight reduction, as present proof is proscribed and inconsistent.
Concerning the research
The current research was carried out from August 2016 to November 2019 at Hvidovre Hospital and the College of Copenhagen. It was accepted by the Regional Ethics Committee in Denmark and the Danish Medicines Company, following Consolidated Requirements of Reporting Trials (CONSORT) tips. Members aged 18-65 with a physique mass index (BMI) of 32-43 offered knowledgeable consent. These with severe persistent diseases, together with diabetes, had been excluded. After an 8-week low-calorie weight loss program (800 kcal/day), individuals who misplaced no less than 5% of their preliminary physique weight had been randomized into 4 teams: train and placebo, liraglutide, a mix of train and liraglutide, or placebo.
The train intervention included a 6-week ramp-up section, adopted by vigorous-intensity group and particular person classes. Liraglutide or placebo was administered each day, beginning at 0.6 mg and growing to three.0 mg or the very best tolerated dose. Month-to-month weight consultations with dietetic help had been offered.
Outcomes included physique weight, composition, and BMD on the hip, lumbar backbone, and forearm, measured by dual-energy x-ray absorptiometry (DXA). Bone turnover markers, plasma sort 1 collagen cross-linked C-telopeptide (P-CTX), and plasma propeptide of sort 1 procollagen (P-P1NP) had been assessed from fasting blood samples. The statistical evaluation used constrained linear blended fashions, adjusting for baseline measurements, with a two-sided P < .05 thought-about vital. Information evaluation occurred from March to April 2023, with further evaluation in February 2024.
Research outcomes
A complete of 195 individuals (imply age 42.84 years; 64% feminine; imply BMI 37.00) accomplished the low-calorie weight loss program and had been randomized into 4 teams: train (48 individuals), liraglutide (49 individuals), mixture (49 individuals), and placebo (49 individuals). BMD measurements had been out there for 158 to 161 individuals at week 52. No individuals had been on osteoporosis medicines, and no fragility fractures occurred. Security outcomes had been reported beforehand.
The imply train quantity was 118 minutes/week at 78% of most coronary heart price within the train group and 111 minutes/week at 79% within the mixture group. Eight individuals accomplished the research on a decrease remedy dose, and 11 discontinued the research remedy however remained within the research.
The estimated imply weight reduction was 7.03 kg within the placebo group, 11.19 kg within the train group, 13.74 kg within the liraglutide group, and 16.88 kg within the mixture group. After the preliminary weight lack of 13.1 kg, the placebo group regained weight, whereas the train and liraglutide teams maintained their weight reduction, and the mix group misplaced further weight. Each the train and liraglutide teams diminished fats proportion and mass, with the mix group displaying the best reductions. The train group elevated lean mass, and the mix group preserved lean mass regardless of vital fats loss.
Modifications in BMD from earlier than the low-calorie weight loss program to week 52 confirmed that the mix group had no vital modifications in BMD in comparison with the placebo on the hip and lumbar backbone. Nevertheless, the liraglutide group skilled a lower in hip and lumbar backbone BMD in comparison with the train and placebo teams. The distal forearm BMD elevated within the train and mixture teams, with no vital variations between the 4 teams. Subgroup analyses by intercourse and age confirmed constant outcomes. Liraglutide and mixture remedies had been related to elevated whole-body BMD in comparison with placebo.
Bone turnover markers confirmed that P-CTX elevated by 27% after the low-calorie weight loss program and decreased in all teams by week 26, with the bottom ranges within the placebo group. P-P1NP elevated by 7% through the low-calorie weight loss program and returned to preliminary ranges by week 52 in all teams.
Conclusions
To summarize, this secondary evaluation of a randomized medical trial examined modifications in site-specific BMD throughout diet-induced weight reduction adopted by a 1-year intervention with liraglutide (3.0 mg/day), train, or their mixture, in comparison with placebo. The mix therapy led to the best weight and fats discount whereas preserving BMD on the hip, backbone, and forearm. Liraglutide alone diminished hip and backbone BMD regardless of weight reduction. Train alone maintained lean mass and preserved hip and backbone BMD. The findings counsel that combining train with GLP-1RA remedy is the simplest technique for weight reduction whereas preserving bone well being.
Journal reference:
- Jensen SBK, Sørensen V, Sandsdal RM, et al. Bone Well being After Train Alone, GLP-1 Receptor Agonist Therapy, or Mixture Therapy: A Secondary Evaluation of a Randomized Medical Trial. JAMA Netw Open. (2024) doi:10.1001/jamanetworkopen.2024.16775, https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820308